The device uses a spectrometer and a side effect-free fluorescent light to examine cervix. The light makes structural and biochemical changes visible to inform the physician on whether the cell is cancerous or not.
This method enables diagnosis 2 years earlier when compared to PAP smear test. Because the abnormal cells have to migrate to superficial tissues to make a diagnosis with this test. A chemiluminescent screening, however, can detect recent-onset abnormalities that are located deep.
Accuracy of chemiluminescent screening is 85 to 95 percent. Screening intervals are identical to conventional screening methods.
The light is not reflected identically by healthy cells and atypical cells with chemical status deteriorated by viruses and the device senses the difference.
The results are expressed low-, moderate- and high-risk and projected on a computer screen. Cells are coded in green, yellow and red, depending on risk level. Thus, recent-onset cellular anomalies at deep locations can be detected.
The physician can make a decision about whether the patient requires a procedure depending on the risk status of cellular changes in cervix.
Necessary procedures are performed, if high-risk is reported for the patient. Patients are asked to be screened at shorter intervals – more frequently than annual intervals – in cases of moderate risk. Intervention is not required if the risk is low.
